US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:35:58 Source:entertainmentViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS
Next:Target starts price war with Walmart by slashing the cost of 5,000 popular items
You may also like
- Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
- Israel marks memorial day, as Palestinians flee Rafah. Follow the latest
- Championship play
- Chris Gotterup wins Myrtle Beach Classic for 1st PGA Tour title
- Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
- Ukraine to face critical phase of war in next two months: commander
- Swedish premier hosts German, Nordic leaders to deepen cooperation shadowed by a threat from Russia
- Alex Scott looks every inch the golden goddess in a figure
- UN Security Council rejects Russia